Universal Time: 20:44  |  Local Time: 20:44 (0h GMT)
Select your timezone:

The Future is Now… Immune Regulation in Transplantation

Tuesday September 15, 2020 - 08:15 to 10:00

Room: Channel 6

360.1 The Regulation of Immune Tolerance by FOXP3 - basic

Ling Lu, People's Republic of China

Liver Surgery
The First Affiliated Hospital of Nanjing Medical University

Biography

Ling Lu, MD, PhD
Associate Director of Surgery,
The First Affiliated Hospital of Nanjing Medical University, Nanjing, China;
Assistant dean, Translational research center, Nanjing Medical University, Nanjing, China;
Professor, Nanjing Medical University, Nanjing, China.
Department of Liver Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Research Interest:
Liver surgery and liver transplantation

----  Damage control in liver surgery

----  Regulatory T cell and transplantation tolerance

----  Organ protection withcontinue machine perfusion


Education:

Visiting Scholar, 2013.08-2014.07, liver transplantation,University of California, Los Angeles, USA

Ph D,Surgery,2010, Nanjing Medical University, Nanjing, China

Post-Doctor, 2008.03-2010.06, Department of Immunology ,University of Southern California, USA

Master of Medicine,Surgery,2007, Nanjing Medical, University, Nanjing, China

Bachelor of Medicine, 2003,Clinical medicine, Nanjing Medical University, Nanjing, China


Honors and Awards:

2019, National talent project "outstanding contributions of young and middle-aged" experts

2018, Top 10 young stars of science and technology in jiangsu province

2017, Jiangsu youth May 4th medal

2017, Provincial science and technology progress award of Jiangsu

2017, Outstanding achievement award for scientific research in Universities

2017, The Chinese medical science and technology award

2017, The Huaxia medical science and technology award


Ongoing Research Projects:

PI, 2019.01, Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, CAMS(No. 2019-I2M-5-035)

PI, 2020.01, TAK1 promotes the progression of non-alcoholic steatohepatitis through YAP/c-Jun interaction in Kupffer cells, NSFC(No. 81971495)

PI, 2016.01, On transplantation immunology , NSFC(No. 81522020)

PI, 2016.01, On the mechanism of chronic rejection mediated by IL-17 with autoantigen ColΙ after liver transplantation, NSFC(No. 81571564)


Selected Papers:

1. Lu L, Joseph Barbi, Fan Pan. The regulation of immune tolerance by FOXP3. Nature Reviews Immunology. 2017 Nov;17(11):703-717.   IF= 39.931

2. Ni X, Tao J, Barbi J, Chen Q2, Park BV, Li Z, Zhang N, Lebid A, Ramaswamy A, Wei P, Zheng Y, Zhang X, Wu X, gnali PDA, Yang C, Li H, PardollD, LuL, PanD, PanF.YAP is essential for Treg mediated suppression of anti-tumor immunity. Cancer Discovery. 2018 Aug;8(8):1026-1043.    IF=20.01

3. Lu L, Yue S, Jiang L, Li C, Zhu Q, Ke M, Lu H, Wang X, Busuttil RW, Ying QL, Kupiec-Weglinski JW, Ke B. Myeloid Notch1 deficiency activates the RhoA/ROCK pathway and aggravates hepatocellular damage in mouse ischemic livers. Hepatology. 2018 Mar;67(3):1041-1055.   IF=13.25

4. Lu Y, Hippen KL, Lemire AL, Gu J, Wang W, Ni X, Ranganathan P, Levine BL, Riley JL, June CH, Turka LA, Munn DH, Garzon R, Lu L(*); Blazar BR(*). miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. Blood. 2016, 128: 1424~1435.     IF=13.164

5. Ni, XH, Kou, W, Gu, J, Wei, P, Wu, X, Peng, H, Tao, JH, Yan, W, Yang, XP, Lebid, A, Park, BV, Chen, ZJ, Tian, YZ, Fu, J, Newman, S, Wang, XM, Shen, HB, Li, B, Blazar, BR, Wang, XH, Barbi, J(*), Pan, F(*), Lu, L(*).TRAF6 directs FOXP3 localization and facilitates regulatory T-cell function through K63-linked ubiquitination. EMBO J. 2019 May 2;38(9). pii: e99766.    IF=11.227

6.Lu L, Lan Q, Li Z, Zhou X, Gu J, Li Q, Wang J, Chen M, Liu Y, Shen Y, Brand DD, Ryffel B, Horwitz DA, Quismorio FP, Liu Z, Li B, Olsen NJ, Zheng SG. Critical role of all-trans retinoic acid in stabilizing human natural regulatory T cells under inflammatory conditions. Proc Natl Acad Sci U S A. 2014; 111(33):E3432-40.    IF=9.674

Presentations by Ling Lu

WebApp Sponsor

© 2024 TTS 2020